AMSBIO CO., LTD. is an IVD medical device, diagnostic reagent developer and manufacturer established in 2000. The company holds more than 11 domestic/overseas patents, and since the COVID-19 pandemic, AMSBIO successfully developed fast COVID-19 PCR reagent which acquired an KFDA EUA on 2020.07. Along with the PCR reagent, AMSBIO has been developing all medical devices, consumables used in the PCR processes. In addition, by introducing mobile laboratory and monitoring platform 'Nightingale Platform', AMSBIO is looking to provide whole diagnostic solution and data managing platform around the world.
AMSBIO's The A+CheQ COVID-19 RT-qPCR Kit is a reagent intended for the qualitative detection of SARS-CoV-2 viral nucleic acids in human upper clinical specimens. This kit is known for its high-speed, high accuracy which detects ORF1ab and N genes of SARS-CoV-2 within 30 minutes.